Trial Profile

A Multicenter, Phase 1, Open-Label, Dose Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABBV 085 (Primary) ; Gemcitabine; Nivolumab; Paclitaxel
Indications Adenocarcinoma; Advanced breast cancer; Head and neck cancer; Non-small cell lung cancer; Osteosarcoma; Pancreatic cancer; Sarcoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors AbbVie

Most Recent Events

17 Sep 2021 Results from NCT02099058, NCT02365662, NCT02462525 and NCT02565758 assessing Neutropenia, presented at the 2021 American College of Clinical Pharmacology Annual Meeting
05 Apr 2021 Results published in the Clinical Cancer Research
21 Mar 2020 Preliminary results presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com